Evidence map›Paper›PMID 31915716›Full record

ArticleOpen forum infectious diseases2020

Antiretroviral Treatment Simplification With 2-Drug Regimens: Impact of Transmitted Drug Resistance Mutations.

Harald H Kessler, Evelyn Stelzl, Anja Blažič, Sanjay R Mehta, Anna S Benezeder, Christina Genger-Hackl, Brigitte I Santner, Antoine Chaillon, Martin Hoenigl

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Harald H KesslerResearch Unit Molecular Diagnostics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
Evelyn StelzlResearch Unit Molecular Diagnostics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
Anja BlažičResearch Unit Molecular Diagnostics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
Sanjay R MehtaDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA.
Anna S BenezederResearch Unit Molecular Diagnostics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
Christina Genger-HacklDepartment of Gastroenterology and Infectious Diseases, Academic Hospital Graz II, Graz, Austria.
Brigitte I SantnerResearch Unit Molecular Diagnostics, Diagnostic and Research Center for Molecular Biomedicine, Medical University of Graz, Graz, Austria.
Antoine ChaillonDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA.
Martin HoeniglDivision of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, California, USA.
Medical University of Graz · ATUniversity of California, San Diego · USUniversity of California System · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
The Prostate as a Reservoir for Residual ReplicationR21AI131971 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHAILLON, ANTOINE · 2018 to 2019
$432k
NCATS NIH HHS UL1 TR001442NIAID NIH HHS P30 AI036214NIAID NIH HHS R21 AI131971
6 · The paper itself

Abstract

The frequency of clinically relevant transmitted drug resistance mutations (DRMs) against drugs used for 2-drug regimens was 15.6%, but only 2% were not eligible for 1 or more 2-drug regimens. More than 50% of patients harboring any clinically relevant DRMs were found to be part of genetic transmission clusters.

Indexed as

dolutegravirHIVlamivudinemolecular epidemiologyrilpivirine

Identifiers

PMID31915716
PMCPMC6942491
OpenAlexW2996713688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.